International Journal of Colorectal Disease

, Volume 28, Issue 10, pp 1401–1406

National trends in intestinal resection for Crohn’s disease in the post-biologic era

  • John P. Burke
  • Yoga Velupillai
  • P. Ronan O’Connell
  • J. Calvin Coffey
Original Article



Prior international datasets have demonstrated equivocal results in the rate of surgical procedures for the treatment of Crohn’s disease (CD) following the introduction of biologic medications. The first biologic medication licensed for use in the Republic of Ireland (ROI) was infliximab in 1999. The current study examined national trends in intestinal resection for CD in the ROI following the introduction of biologic medications.


The Irish Hospital In-Patient Enquiry database was examined for the period 2000–2010. Cases of CD and relevant surgical interventions were identified using International Classification of Diseases, ninth and tenth editions. Using Irish census data to establish population denominators, trends in population-based procedure rates were examined. Trends were tested for significance with Spearman rank tests.


From 2000 to 2010, there were 11,796 patient admissions with a principal diagnosis of CD. The rates of admission for CD overall (r2 = −0.191, P = 0.574) and for emergencies (r2 = 0.055, P = 0.873) did not change; however, elective admissions reduced (r2 = −0.636, P = 0.035). The mean length of stay reduced (r2 = −0.783, P = 0.004). The rates of small bowel/right colon procedures (r2 = 0.282, P = 0.401) and proctectomy (r2 = −0.209, P = 0.537) did not change. Left colon procedures reduced (r2 = −0.800, P = 0.003) while the rate of total colectomy increased (r2 = 0.718, P = 0.013).


During the decade following the introduction of biologic medications in the ROI, the rate of elective hospitalization and length of stay reduced. However, there has not been a dramatic reduction in the rate of intestinal resection for Crohn’s disease at a population level.


Crohn’s disease Surgery Infliximab Biologic Epidemiology 


  1. 1.
    Van Assche G, Vermeire S, Rutgeerts P (2010) The potential for disease modification in Crohn’s disease. Nat Rev Gastroenterol Hepatol 7(2):79–85PubMedCrossRefGoogle Scholar
  2. 2.
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549PubMedCrossRefGoogle Scholar
  3. 3.
    Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350(9):876–885PubMedCrossRefGoogle Scholar
  4. 4.
    Burke JP, Mulsow JJ, O’Keane C, Docherty NG, Watson RW, O’Connell PR (2007) Fibrogenesis in Crohn’s disease. Am J Gastroenterol 102(2):439–448PubMedCrossRefGoogle Scholar
  5. 5.
    Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 121(5):1145–1157PubMedCrossRefGoogle Scholar
  6. 6.
    Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF et al (2012) Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 142(5):1102–11 e2PubMedCrossRefGoogle Scholar
  7. 7.
    Lichtenstein GR, Abreu MT, Cohen R, Tremaine W (2006) American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130(3):935–939PubMedCrossRefGoogle Scholar
  8. 8.
    Behm BW, Bickston SJ (2008) Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 1:CD006893PubMedGoogle Scholar
  9. 9.
    Feagan BG, Lemann M, Befrits R, Connell W, D’Haens G, Ghosh S et al (2012) Recommendations for the treatment of Crohn’s disease with tumor necrosis factor antagonists: an expert consensus report. Inflammatory bowel diseases 18(1):152–160PubMedCrossRefGoogle Scholar
  10. 10.
    Rubenstein JH, Chong RY, Cohen RD (2002) Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol 35(2):151–156PubMedCrossRefGoogle Scholar
  11. 11.
    Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB (2010) Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut 59(9):1200–1206PubMedCrossRefGoogle Scholar
  12. 12.
    Jones DW, Finlayson SR (2010) Trends in surgery for Crohn’s disease in the era of infliximab. Ann Surg 252(2):307–312PubMedCrossRefGoogle Scholar
  13. 13.
    Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP (2005) Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 54(2):237–241PubMedCrossRefGoogle Scholar
  14. 14.
    Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR (2007) Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflammatory bowel diseases 13(12):1529–1535PubMedCrossRefGoogle Scholar
  15. 15.
    Slattery E, Keegan D, Hyland J, O’Donoghue D, Mulcahy HE (2011) Surgery, Crohn’s disease, and the biological era: has there been an impact? J Clin Gastroenterol 45(8):691–693PubMedCrossRefGoogle Scholar
  16. 16.
    Quan H, Parsons GA, Ghali WA (2004) Validity of procedure codes in International Classification of Diseases, 9th revision, clinical modification administrative data. Medical Care 42(8):801–809PubMedCrossRefGoogle Scholar
  17. 17.
    Bewtra M, Su C, Lewis JD (2007) Trends in hospitalization rates for inflammatory bowel disease in the United States. Clinical Gastroenterol Hepatol 5(5):597–601, The official clinical practice journal of the American Gastroenterological AssociationCrossRefGoogle Scholar
  18. 18.
    Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F (1997) Prospective study of the features, indications, and surgical treatment in 513 consecutive patients affected by Crohn’s disease. Surgery 122(4):661–667, discussion 67–8PubMedCrossRefGoogle Scholar
  19. 19.
    Prabhakar LP, Laramee C, Nelson H, Dozois RR (1997) Avoiding a stoma: role for segmental or abdominal colectomy in Crohn’s colitis. Dis Colon Rectum 40(1):71–78PubMedCrossRefGoogle Scholar
  20. 20.
    Andersson P, Olaison G, Bodemar G, Nystrom PO, Sjodahl R (2002) Surgery for Crohn colitis over a twenty-eight-year period: fewer stomas and the replacement of total colectomy by segmental resection. Scand J Gastroenterol 37(1):68–73PubMedCrossRefGoogle Scholar
  21. 21.
    Tekkis PP, Purkayastha S, Lanitis S, Athanasiou T, Heriot AG, Orchard TR et al (2006) A comparison of segmental vs subtotal/total colectomy for colonic Crohn’s disease: a meta-analysis. Colorectal Dis 8(2):82–90, The official journal of the Association of Coloproctology of Great Britain and IrelandPubMedCrossRefGoogle Scholar
  22. 22.
    Tang DH, Armstrong EP, Lee JK (2012) Cost-utility analysis of biologic treatments for moderate-to-severe Crohn’s disease. Pharmacotherapy 32(6):515–526PubMedCrossRefGoogle Scholar
  23. 23.
    D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371(9613):660–667PubMedCrossRefGoogle Scholar
  24. 24.
    Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362(15):1383–1395PubMedCrossRefGoogle Scholar
  25. 25.
    Anjum A, von Allmen R, Greenhalgh R, Powell JT (2012) Explaining the decrease in mortality from abdominal aortic aneurysm rupture. Br J Surg 99(5):637–645PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • John P. Burke
    • 1
  • Yoga Velupillai
    • 2
  • P. Ronan O’Connell
    • 3
  • J. Calvin Coffey
    • 1
    • 2
    • 4
  1. 1.Department of SurgeryUniversity Hospital LimerickLimerickIreland
  2. 2.Graduate Entry Medical SchoolUniversity of LimerickLimerickIreland
  3. 3.Centre for Colorectal Disease, St Vincent’s University Hospital and School of Medicine and Medical SciencesUniversity College DublinDublinIreland
  4. 4.Centre for Interventions in Infection, Inflammation and Immunity (4i)University of LimerickLimerickIreland

Personalised recommendations